Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationSergio Giralt, Richard E. Champlin, Peter F. Thall et al.|Blood|2001Cited by 516
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Nathan Fowler et al.|New England Journal of Medicine|2019Cited by 502
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Börje S. Andersson, Daniel R. Couriel et al.|Blood|2004Cited by 422
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemiaXavier C. Badoux, William G. Wierda, Xuemei Wang et al.|Blood|2011Cited by 63